1. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo;Moulder;Cancer Res,2001
2. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible, dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinoma;Burris;J Clin Oncol,2005
3. A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens;Blackwell;Ann Oncol,2004
4. A phase II, open-label, multi-center study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab- containing regimens;Burstein;Ann Oncol,2004
5. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metatstatic breast cancer;Gomez;J Clin Oncol,2005